Human Herpesviruses


Book Description

This comprehensive account of the human herpesviruses provides an encyclopedic overview of their basic virology and clinical manifestations. This group of viruses includes human simplex type 1 and 2, Epstein–Barr virus, Kaposi's Sarcoma-associated herpesvirus, cytomegalovirus, HHV6A, 6B and 7, and varicella-zoster virus. The viral diseases and cancers they cause are significant and often recurrent. Their prevalence in the developed world accounts for a major burden of disease, and as a result there is a great deal of research into the pathophysiology of infection and immunobiology. Another important area covered within this volume concerns antiviral therapy and the development of vaccines. All these aspects are covered in depth, both scientifically and in terms of clinical guidelines for patient care. The text is illustrated generously throughout and is fully referenced to the latest research and developments.




Antiviral Chemotherapy


Book Description

Considerable advances have been made in the treatment of antiviral diseases over the last decade. Several new drugs have been introduced while new clinical information has been gathered on the efficacy of existing drugs. This study aims to provide an examination of the basic science (drug formulae, structure and biochemical activity) and clinical information (usage and efficacy) on chemotherapy, as well as describing future potentials.




Immunotherapy for Infectious Diseases


Book Description

In Immunotherapy for Infectious Disease, Jeffrey M. Jacobson, MD, and a panel of leading researchers review the state-of-the-art for treating various infections-particularly HIV-by manipulating the immune system's response rather than by chemical drugs. The contributors synthesize the principles of immune defense on the molecular level (monoclonal antibodies, vaccines, methods of antigen presentation, and cytokines and cytokine antagonists), as well as on the cellular and clinical levels levels as a protection against infection. The review of the current state of anti-HIV immunotherapy covers HIV-specific passive and active immunization strategies, gene therapy, and host cell-targeted approaches for treating HIV infection and restoring immune function.




Antimicrobial Stewardship: Where We've Come and Where We're Going, An Issue of Infectious Disease Clinics of North America, E-Book


Book Description

In this issue of Infectious Disease Clinics of North America, guest editors Drs. Emily Sydnor Spivak and Sage Greenlee bring their considerable expertise to the topic of Antimicrobial Stewardship: Where We Have Come and Where We Are Going. Throughout the last decade, the field of antimicrobial stewardship has undergone exponential growth due to heightened awareness of antimicrobial use and emerging multidrug-resistant organisms. Additionally, the COVID-19 pandemic highlighted systemic and persistent health disparities in the United States. In this issue, top experts provide a recap of the progress made over the last decade in antimicrobial stewardship and provide direction for next steps in this ever-growing field. - Contains 12 practice-oriented topics including antimicrobial stewardship and pandemic preparedness: lessons learned from COVID-19; health equity considerations; antimicrobial stewardship at transitions of care; antimicrobial stewardship in immunocompromised populations; health system and tele-antimicrobial stewardship: the role of building networks; and more. - Provides in-depth clinical reviews on antimicrobial stewardship, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.




Immunotherapy for Infectious Diseases


Book Description

In Immunotherapy for Infectious Disease, Jeffrey M. Jacobson, MD, and a panel of leading researchers review the state-of-the-art for treating various infections-particularly HIV-by manipulating the immune system's response rather than by chemical drugs. The contributors synthesize the principles of immune defense on the molecular level (monoclonal antibodies, vaccines, methods of antigen presentation, and cytokines and cytokine antagonists), as well as on the cellular and clinical levels levels as a protection against infection. The review of the current state of anti-HIV immunotherapy covers HIV-specific passive and active immunization strategies, gene therapy, and host cell-targeted approaches for treating HIV infection and restoring immune function.




Global Tuberculosis Report 2019


Book Description

WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of recommended global TB strategies and targets endorsed by WHO?s Member States, broader development goals set by the United Nations (UN) and targets set in the political declaration at the first UN high-level meeting on TB (held in September 2018). The 2019 edition of the global TB report was released on 17 October 2019. The data in this report are updated annually. Please note that direct comparisons between estimates of TB disease burden in the latest report and previous reports are not appropriate. The most recent time-series of estimates are published in the 2019 global TB report.




Immunological Screening and Immunotherapy in Critically ill Patients with Abdominal Infections


Book Description

Over two decades an abundance of knowledge has been accumulated focus ing on the understanding of the molecular and cellular pathomechanisms of stressful conditions like systemic inflammation and sepsis. We have learned that there is a clear correlation between the magnitude of the inciting traumatic event and the degree of inflammatory dysbalance. The immunoinflammatory disintegration comprises a simultaneous col lapse of the otherwise very smoothly balanced pro- and antiinflammatory vectors of cytokine regulation. Most recently, we understood that it is predominantly the dysregulation of antiinflammatory mediators that plays a pivotal role for the phenomenon of trauma-induced depression or paralysis of cell-mediated immune responses. The substantial intellectual and logistic investments of numerous investi gators towards understanding the biology of sepsis inevitably lead us towards a rewarding status in terms of reaching spheres of clinical relevance. From the evolutionary collection of a multitude of ex-vivo and in-vivo immuno mechanistic parameters, some were found to represent most significant bio logical markers to support the clinician to characterize better the severity of inflammatory illness and to predict outcome. Chapter one of this book, authored by G. Grass and E.A.M. Neugebauer, analyses elegantly our current knowledge on the assessment of the immuno logical status in terms of risk and prognosis of sepsis.




Novel Technologies for Vaccine Development


Book Description

This book presents a detailed overview of the development of new viral vector-based vaccines before discussing two major applications: preventive vaccines for infectious diseases and therapeutic cancer vaccines. Viral vector-based vaccines hold a great potential for development into successful pharmaceutical products and several examples at the advanced pre-clinical or clinical stage are presented. Nevertheless, the most efforts were focused on novel and very innovative technologies for new generation of vector-based vaccines. Furthermore, specific topics such as delivery and adjuvant and protection strategies for cell-mediated-based vaccines are presented. Given its scope, the book is a “must read” for all those involved in vaccine development, both in academia and industrial vaccine development.




A National Strategy for the Elimination of Hepatitis B and C


Book Description

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the second of two, builds off the conclusions of the first report and outlines a strategy for hepatitis reduction over time and specific actions to achieve them.